NK cells
TILs
Blood DCs and Mo-DCs
Tregs
γδ T cells
Allogeneic cell therapies
Content
- NK cells
- TILs
- Blood DCs and Mo-DCs
- Tregs
- γδ T cells
- Allogeneic cell therapies
Cell therapy is a big promise for the future. Our tools help you to design and enhance the body's immune system for efficient targeting. Turn your ideas into reality and take the next step with automated and closed system solutions for cell manufacturing.
NK cells
TILs
Blood DCs and Mo-DCs
Tregs
γδ T cells
Allogeneic cell therapies
With this workflow you can rely on fast and easy isolation of pure NK cells or NK cell subsets and superior NK cell expansion. Furthermore, it uses optimized flow cytometry reagents for phenotyping and functional analyses.
Clinical-grade natural killer (NK) cell isolation can be enabled in a two-step, fully automated manner within a closed system on the CliniMACS Prodigy. Additionally, it is possible to use the CliniMACS Prodigy for NK cell expansion or generation of engineered NK cells. Proceed to application page
The number and composition of tumor-infiltrating leukocytes (TILs) is highly variable. A reliable analysis of TILs and especially TIL subpopulations calls for efficient isolation strategies. In this workflow, gentle tumor dissociation preserves cell surface epitopes and pre-enrichment allows for improved downstream analysis. It is applicable for manual single-sample separation up to fully automated high-throughput separation.
The CliniMACS Prodigy® Tumor Reactive T (TRT) Cell Process offers a new, adaptable platform for scientists and clinicians working on tumor-infiltrating leukocyte (TIL) therapy, and can be tailored to the individual user’s desired indication and methodology. With our TRT process, it is possible to stimulate and isolate tumor-reactive T cells and then expand them in a closed, automated, GMP-compliant system in as little as two weeks. Furthermore, specific tumor-reactive T cell populations can also be isolated with GMP-compliant cell sorting using the MACSQuant® Tyto® Cell Sorter.
Isolation of monocytes and generation of monocyte-derived dendritic cells. This workflow is optimized for easy and fast isolation of CD14+ monocytes and generation of monocyte-derived DCs (Mo-DCs). Plus, it enables translation of your Mo-DC for clinical research purposes.
Take advantage of the automated and closed system of the CliniMACS Prodigy® Platform to generate dendritic cells from peripheral blood monocytes. The CliniMACS Prodigy LP-14 Mo-DC System combined with our MACS® GMP Products is all you need for consistent and reliable manufacturing of monocyte-derived dendritic cells (Mo-DC) at clinical scale.
The CliniMACS Prodigy® BloodDC PreDepletion System and the CliniMACS Prodigy BloodDC Enrichment and Culture System have been developed for the joint enrichment of dendritic cell (DC) subsets from non-mobilized apheresis products, followed by maturation and antigen loading. Steps of each system take place in the appropriate tubing set: CliniMACS Prodigy TS 320 for depletion and biotin labeling and CliniMACS Prodigy TS 510 for enrichment and cultivation.
Comprehensive solutions for your Treg human and mouse research
We provide the means for a fast and gentle isolation and flow sorting of regulatory T cells (Treg cells) as well as distinct Treg subsets. You have the possibility of optimized culture, activation, and expansion, as well as phenotyping and functional analysis of Treg cells.
Flexible strategies for closed system Treg cell enrichment and isolation. Our automated manufacturing processes on the CliniMACS Prodigy and CliniMACS Plus expand your possibilities.
The CliniMACS Prodigy® Platform enables the automated manufacturing of γδ T cells. All processing steps – from efficient γδ T cell enrichment, activation, and expansion to optional engineering by viral transduction and final product harvest – are carried out in a closed system. The result is a robust and simplified workflow that facilitates the development of novel γδ T cell therapies.
At Miltenyi Biotec, we support the entire spectrum of cell therapy modalities, empowering both autologous and allogeneic approaches whether in clinical research or commercial settings.
Our CliniMACS® Instruments, consumables, and reagents provide essential tools needed to achieve optimal growth conditions and create streamlined scalable allogeneic workflows. With flexibility built in, you can seamlessly integrate external expansion systems, such as bioreactors, to meet diverse manufacturing needs. This adaptability makes it easier to advance modalities like allogeneic stem cell therapy or allogeneic CAR T cell therapy.